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ABSTRACT 
 
The present studies describe recent progress toward the synthesis of the 
thebaine. Model substrates were synthesized using pyridazine derivatives as a 
starting material, which allowed to assess the key Diels-Alder reaction as a route 
to construct the thebaine core.  
  
iii 
 
ACKOWLEDGEMENTS 
This dissertation would not have been possible without the guidance and 
the help of several individuals who in one way or another contributed and 
extended their valuable assistance in the preparation and completion of this study.  
I express my warmest gratitude to Brock University, for not only blessing 
me with helpful teaching but also introducing me to a very constructive 
environment and comfortable place of work. 
Next I would like to express my sincere gratitude to my research 
supervisor, Dr. Tomas Hudlicky. His valuable suggestions and encouragement 
have been instrumental in the completion of this work. Without his effort and 
constant support, this work would not have shaped up the way it has.  
I would like to specially thank Dr. Sergio Alatorre, Dr. Ian Taschner and 
Dr. John Trant who really helped me in the completion of this work. I would also 
like to thank the members of my graduate committee, Dr.  Tony Yan and Dr. Paul 
Zelisko for their guidance. 
I would also like to thank my parents Umesh and Vineeta Gupta, the most 
important people in my life. They have always encouraged me and have been my 
best support through the years. I owe a special debt of gratitude to my colleagues 
for their valuable support and help throughout the course of my work. Last, but 
not the least I would like to thank all those who have supported me directly or 
indirectly in the completion of my dissertation. 
iv 
 
TABLE OF CONTENTS 
 
ABSTRACT                        i 
ACKNOWLEGMENTS       ii 
LIST OF TABLES        vi  
LIST OF SCHEMES        vii 
LIST OF FIGURES         x 
LIST OF ABBREVIATIONS      xii 
I.  Introduction        1 
II. Historical         3 
     II-1 Historical overview, extraction and biosynthesis of Morphine 3 
     II-2 Morphine Alkaloids: Synthetic approaches by [4 +2] cycloaddition 6  
     II-3 Pyridazine        25 
II-3.1 Use in synthetic chemistry     25 
II-3.2 Use in Diels-Alder reactions     33 
     II-4 Previous approaches in Hudlicky group towards the synthesis of          
 thebaine        36 
III. Discussion         45 
     III-1 Introduction        45 
     III-2 Model study to construct C and E ring of thebaine   46 
     III-3 Model study to construct D, C and E ring of thebaine  50 
     III-4 Model studies using bis-pyridazine derivative   57 
IV. Conclusions and Future Work      63 
V. Experimental Section       67 
v 
 
     V-1 General Experimental Details     67 
     V-2 Detailed Experimental Details     68  
VI. Selected Spectra        85 
VII. References        96 
VIII. Vita         100 
 
  
vi 
 
LIST OF TABLES 
Table 1. Different conditions for improving the yield of compound 10. 48 
Table 2. Attempted condition to make compound 217.   51 
Table 3. Conditioned to synthesise the 217 with mix anhydride strategy. 53 
Table 4. Conditioned to synthesise the 217 with lactone.   53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF SCHEMES 
Scheme 1. Gates’ Diels Alder cycloadduct intermediate synthesis.  7 
Scheme 2. Synthesis of intermediate 33.     8 
Scheme 3. The remaining transformations to morphine.   9 
Scheme 4. Cignanek’s synthesis of the morphinan skeleton.  10 
Scheme 5. Ciganek’s undesired cycloadduct synthesis of the morphine  
skeleton         11 
Scheme 6. Synthesis of intermediate compound 54.    12 
Scheme 7. Tius’s synthesis of thebainone-A.    13 
Scheme 8. Model studies for morphine synthesis.    15 
Scheme 9. Hudlicky’s correction of morphine skeleton structure.  16 
Scheme 10. Hudlicky’s strategy for the B, C, D ring system synthesis of 
morphine.           17 
Scheme 11. Proposed transition state postulated for model isoquinoline 
cyclizations         19 
Scheme 12. Morphine synthons.      20 
Scheme 13.  Rodrigo strategy to construct morphine skeleton.  21 
Scheme 14. Rodrigo’s Diels-Alder/Cope approach to phenanthrofurans 22 
Scheme 15. Stork’s synthesis of thebaine     25 
Scheme 16. Nucleophic substitution of pyridazine.    28 
Scheme 17. Unsymmmetrically disubstituted pyridazine synthesis.  29 
Scheme 18. Ortho subsittution of pyridazine using a zinc diamide-lithium amide 
mixture.         30 
viii 
 
Scheme 19. Zincation of pyridazine.      30 
Scheme 20.  Pyridazine with directing group.    30 
Scheme 21. Ortho-lithiation of pyridazine with chiral molecules.  31 
Scheme 22. Cross coupling of pyridazine.     32 
Scheme 23. Amination of compound 147     33 
Scheme 24. Intermolecular hetero Diels-Alder reactions example.  33 
Scheme 25. Intramolecular Diels–Alder reactions of pyridazines.  34 
Scheme 26. Effect of alkyne side chain and heteroatom on Diels-Alder  
Reaction         35 
Scheme 27. Effect of subsitution of pyridazine ring on Diels-Alder 
Reaction         35 
Scheme 28. Effect of subsitution of alkyne side chain on Diels-Alder  
Reaction         36 
Scheme 29. Thiophene strategy towards the synthesis of thebaine.  38 
Scheme 30.         39 
Scheme 31.Thiophene based model compound synthesis route.  40 
Scheme 32. Epoxy products.       41 
Scheme 33. Furan based model compound.     42 
Scheme 34. Thermal Diels-Alder reaction attempt.     42 
Scheme 35. Diels-Alder reaction attempt using bis-pyridazine strategy.  44 
Scheme 36. Synthesis of pyridazine amine 9 from pyridaine 5.  48 
Scheme37. Synthesis of pyridazine amine 9 from pyridaine 11.  49 
Scheme38. Diels-Alder successful attempt.     49 
ix 
 
Scheme 39. Dihydrofuran ester synthesis.     50 
Scheme 40. Synthesis of a potassium salt of dihydrofuranester.  52 
Scheme 41. Diels-Alder reaction precursor 217 which underwent 
an intramolecular Diels-Alder reaction to yield 222    54 
Scheme 42. Synthesis of furan acetic acid.     56 
Scheme 43. Attempted Diels-Alder reaction with 229.   57 
Scheme 44. Synthesis of Bis-pyridazine derivative.    58 
Scheme 45. Diels-Alder reaction attempt of 205 in different condition. 59 
Scheme 46. Synthesis of compound 237.      60 
Scheme 47. Cross coupling reactions attempt.    61 
Scheme 48. Bis pyridazine amine synthesis.     62 
Scheme 49. Unexpected elimination reaction.    63 
Scheme 50. Diels-Alder attempt with compound 256.   65 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES 
Figure 1.  Retrosynthetic analysis for the symmetry-based synthesis  
of thebaine.         1 
Figure 2. Retrosynthetic analysis for the model studies of thebaine. 2 
Figure 3.  Some morphine alkaloids.      3 
Figure 4.  Biosynthesis of morphine alkaloids.    5 
Figure 5.  Cignek’s strategy to construct morphine skeleton.  9 
Figure 6.  Tius retro analysis of morphine.     11 
Figure 7.  Hudlicky’s Diels-Alder strategy.     14 
Figure 8.  Hudlicky’s approach for isoquinoline morphine synthons. 18 
Figure 9.  Electrophilic substitution with pyridazine.   25 
Figure 10. Alkylation of pyridazine.      26 
Figure 11. Oxidation of pyridazine.      27 
Figure 12. Electrophilic substitution reactions at carbon of pyridazine. 27 
Figure 13. C-H activation from LiTMP.     29 
Figure 14. Stille and Suzuki coupling reactions of pyridazine.  32 
Figure 15.  Investigation of intramolecular  cycloaddition of pyridazine. 34 
Figure 16.  Retrosynthetic analysis of thebaine using thiophene as a masked 
diene.           36 
Figure 17.  Retro analysis of thiophene based model.   39 
Figure 18.  Diels-Alder strategy towards the synthesis of thebaine.  43 
Figure 19.  Retro synthetic analysis for simple model studies of thebaine. 45 
Figure 20.  Simply model study to construct C and E ring of thebaine. 46 
xi 
 
Figure 21.  Ortholithiation of pyridazine.     48 
Figure 22.  Model study with dihydrofuran ester.    50 
Figure 23.  Attempted condition to make compound 217.    51 
Figure 24.  Mix anhydride strategy to get an amide.    52 
Figure 25.  Model study with 9 and 195.     55 
Figure 26.  Furan strategy towards the synthesis of thebaine.  55 
Figure 27.  Bis-pyridazine-based model compounds.    60 
Figure 28. Retro synthetic analysis based of first Diels-Alder reaction. 64 
Figure 29. Envisioned Diels-Alder precursor compounds.   64 
Figure 30. Future Diels-Alder precursor compounds.   66 
 
 
 
 
xii 
 
LIST OF ABBREVIATIONS 
Ac  Acetyl 
Acac  Acetylacetonate 
BTIB  bis-(Trifluoroacetoxy)iodobenzene 
Bz                    Benzoyl 
CDI  Carbonyldiimidazole 
DBU  1,8-Diazobicyclo[5.4.0]undec-7-ene 
DCC  Dicyclohexylcarbodiimide 
DCM              Dichloromethane 
DIBAL-H Diisobutylaluminum hydride 
DMAP  Dimethylamino pyridine 
DME  Dimethoxyethane 
DMF  Dimethylformamide 
DMS  Dimethylsulfide 
DMSO  Dimethylsulfoxide 
Dppf  1,1'-Bis(diphenylphosphino)ferrocene 
EDC  N-(3-Dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride 
Et2O  Diethylether 
Et3N  Triethylamine 
HBTU  N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium      
                        hexafluorophosphate, O-(Benzotriazol-1-yl)-N,N,N′,N′-         
                        tetramethyluronium hexafluorophosphate 
HMPA  Hexamethylphosphoramide 
xiii 
 
                                                                                                                                           
Imid  Imidazole 
i
Pr  Isopropyl 
KHMDS Potassium hexamethyldisilazide 
LAH  Lithium aluminum hydride 
LDA  Lithium diisopropylamide 
LUMO Lowest unoccupied molecular orbital 
LiTMP lithium 2,2,6,6-tetramethylpiperidide 
m-CPBA meta-Chloroperoxybenzoic acid 
Me  Methyl 
MsCl  Mesyl chloride 
nBu  n-Butyl 
NBS  N-Bromosuccinimide 
nPr  n-Propyl 
N2H2  Hydrazine 
NMR  Nuclear magnetic resonance 
nOe  Nuclear Overhauser effect 
PAD  Potassium azodicarboxylate 
PCC  Pyridinium chlorochromate 
Py  Pyridine 
TBAF  Tetrabutylammonium fluoride 
THF  Tetrahydrofuran 
TLC  Thin layer chromatography 
xiv 
 
TMEDA Tetramethylethylenediamine 
TMS  Trimethylsilyl 
Ts  Tosyl  
t
Bu  Tertiarybutyl 
Ph  Phenyl 
PPh3  Triphenylphosphine
1 
 
I.  Introduction 
Recently, thebaine has gained increasing notoriety as an important 
intermediate for the synthesis of other morphinans. An efficient total synthesis 
could be used to supplement or replace its natural supply. Oxycodone, 
oxymorphone, naloxone, naltrexone, etorphine, and buprenorphine can all be 
manufactured through semi-synthesis from thebaine. 
The proposed synthesis of thebaine is based on the latent pseudo-
symmetry that is present in the target molecule, as shown in Figure 1. 
 
Figure 1.  Retrosynthetic analysis for the symmetry-based synthesis of thebaine. 
In this thesis model studies will be conducted and the key model 
compounds 6 and 7 (Figure 2) will be constructed through an intramolecular 
Diels-Alder reaction. Compound 6 consists of rings D, C and E; and compound 7 
consists of rings C and E of the morphine alkaloid core.  
In order to determine the viability of the [4+2] reaction, pyridazine 
derivatives will be used as dienes. An allylic, dihydrofuranyl and furanyl 
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derivatives will be used as dienophiles for the Diels-Alder reaction, as shown in 
Figure 2. 
Based on the outcome of the initial studies, approaches to the entire core 
of thebaine will be pursued.   
 
 
Figure 2. Retrosynthetic analysis for the model studies of thebaine. 
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II. Historical 
II-1 Historical overview, extraction, and biosynthesis of morphine 
Morphine and its congeners have attracted the attention of chemists for 
decades.  
 
Figure 3.  Structure of some morphine alkaloids. 
Sumerians used opium for the  first time in about 3400 BC.
1,2
 Serturner 
isolated the morphine in its pure form in 1805.
3
 Laurent disclosed its correct 
empirical formula, C17H19NO3, in 1847.
4
 The phenanthrene core of morphine was 
confirmed by von Gerichten, when morphine was treated with Zn dust at 300 °C.
5 
Later, Hofman and Pshorr confirmed the presence of an oxygenated phenanthrene 
skeleton from degrading experiments of morphine and codeine.
6,7
 Robinson and 
Gulland proposed the correct structure of morphine in 1925
8
 and it was confirmed 
by Gates in 1952 through his landmark synthesis of morphine.
9 
 
Opium is isolated from the seed pods of P. somniferum. Morphine 
alkaloids are produced at the certain time of the year therefore time of harvesting 
opium is important. Seed pods are incised when they ripen and rubb from the 
surface to collect the latex. This latex contains a number of alkaloids with 
4 
 
morphine as a major constituent. Morphine is isolated from the latex by various 
methods depending on time and cost.
2
 
The biosynthetic summary of morphine starts from the amino acid 
tyrosine, as shown in Figure 4. Dopamine and 4-hydroxyphenylacetaldehyde are 
condensed to (S)-norcoclaurine from tyrosine by two different pathways. N-
Methylation, oxidation, and further methylation of (S)-norcoclaurine gives (S)-
reticuline which is epimerized to (R)-reticuline. The coupling of the carbon atoms 
12 and 13 of (R)-reticuline forms salutaridine which is transformed to thebaine in 
three steps. Demethylation, migration of the double bond, and reduction of the 
ketone group leads to codeine and further demethylation yields morphine.
10
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
Figure 4.  Biosynthesis of morphine alkaloids. 
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II-2 Morphine Alkaloids: Synthetic approaches by [4 +2] cycloaddition 
The first total synthesis of morphine was accomplished by Gates in 1952 
and since then a number of total syntheses of the morphine alkaloids has been 
carried out. In the field of morphine synthesis, many synthetic strategies have 
been developed.  One of the most versatile reactions known to organic chemists is 
the Diels-Alder reaction. It was named after Otto Diels and Kurt Alder, the 
scientists who discovered this reaction. This discovery led them to win the Nobel 
Prize in Chemistry in the year 1950. This reaction has been successfully utilized 
in the synthesis of many complex organic molecules including morphine. 
The historical aspects of morphine in terms of the Diels-Alder reaction are 
summarized below. 
Gates (1952)
9
 
The total synthesis accomplished by Gates in 1952 used the Diels-Alder 
strategy, specifically the intermolecular version of the Diels–Alder reaction. The 
2,6-dihydronaphthalene 24 was subjected to benzoylation, nitrosation, and 
reduction to the amino naphthol and was oxidized without the isolation of the 
naphthoquinone. The quinone was reduced with sulfur dioxide and the catechol 
unit was converted to its dimethoxy ether. The benzoate was cleaved by treatment 
with methanolic KOH and the nitrosation-reduction sequence was repeated to 
attain napthoquinone 26. A preparative modification of the Craven’s test was 
employed to introduce the cyanoethylacetate functionality into 26 and in a 
subsequent step the ester was cleaved by Claisen alkali. Compound 27 was one of 
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the intermediate compounds served as the precursor for the key cycloaddition 
reaction along with butadiene to construct the C-ring of the morphine skeleton. 
 
Reagents and Conditions: a) BzCl, py, dioxane (72%); b) NaNO2, AcOH (88%); 
c) AcOH, Pd(C), H2, then FeCl3 (85%); d) SO2, MeOH (91%); (e) K2CO3, 
dimethyl sulphite; f) KOH, MeOH (87%); g) NaNO2, AcOH, Pd(C), H2, then 
FeCl3 (82%); h) ethyl cyanoacetate Et3N, then K3Fe(CN)6 (84%); i) Claisen’s 
alkali (97%); j) butadiene (66%). 
Scheme 1. Gates’ Diels-Alder cycloadduct intermediates synthesis. 
The D ring of morphine was formed in a rare reductive cyclization 
reaction mediated by medium-pressure hydrogenation using a copper chromite 
catalyst at 130 ˚C. Standard Wolff-Kischner reduction of the C-10 ketone 
followed by alkylation of the amide with iodomethane and resolution with the 
enantiomorphic dibenzoyltartrate salts yielded structure 31. Oxygenation at the C-
6 centre was accomplished by treatment of 31 with dilute sulfuric acid and 
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oxidation with potassium t-butoxide-benzophenone resulted in ketone derivative 
33.  
 
Reagents and Conditions: a) H2, copper chromite (50%); b) KOH, N2H4; c) 
NaH, MeI; d) LAH (54%) then dibenzoyl tartrate resolution; e) dilute H2SO4 
(28%); f) KOH, ethylene glycol; g) 
t
BuOK, Ph2CO (89%). 
Scheme 2. Synthesis of intermediate 33. 
The remaining transformations to morphine mainly consisted of the 
bromination, hydrazone formation, introduction of the α,β-unsaturation unit, and 
dihydrobenzofuran ring closure to complete the synthesis of morphine.   
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Reagents and Conditions: a) Br2, AcOH, 2,4-dinitrophenylhydrazine (41%); (b) 
12N HCl (60%); (c) PtO2, H2 (80%); (d) Br2, AcOH, 2,4-dinitrophenylhydrazine 
(26%); (e) 12N HCl (27%); (f) LAH (quant); (g) Py•HCl (34%). 
Scheme 3.  The remaining transformations to morphine. 
Ciganek (1981)
11
 
Ciganek visualized that a morphine skeleton lacking the B ring could be 
constructed using a Diels-Alder strategy.  
 
Figure 5.  Ciganek’s strategy to construct morphine skeleton.  
In his unique synthesis benzofuran, as a dienophile, was the first reported 
application of a benzofuran unit as a dienophile part of a Diels-Alder reaction. 
10 
 
Ciganek synthesiszed 40 from 39 through an intramoleclar cycloaddition reaction 
which was carried out in 1,2,4-trichlorobenzene at 215°C for 10 h. The 
cycloaddtion adduct was subjected to hydrogenation and reduction to yield the 
morphine skeleton with correct stereochemistry. 
 
Reagents and Conditions: a) 215 ˚C; b) H2, Pd/C; c) BH3•DMS; d) nPrS
-
K
+
, 
DMF.   
Scheme 4. Ciganek’s synthesis of the morphinan skeleton. 
At the same time Ciganek also utilized N-(7-methoxy-3-benzofuranethyl)-
N-(cyclopropylmethy1) amide of 2,4-pentadienoic acid  to construct the morphine 
skeleton but this time cylcloaddition gave the  undesired  cycloadduct  at 240 °C 
in toluene. 
11 
 
 
Reagents and Conditions: a) 240 ˚C; b) H2, Pd/C; c) BH3•DMS; d) nPrS
-
K
+
, 
DMF.   
Scheme 5. Ciganek’s undesired cycloadduct synthesis of the morphine skeleton. 
Tius (1991)
12
 
In 1991 Tius visualised that morphine could be constructed from a non 
aromatic precursor through a Diels-Alder strategy.  
 
Figure 6.  Tius’ retro synthetic analysis of the morphine.  
He used quinoline and styrene equivalent for a Diels-Alder reaction to 
construct the A, B and C fused ring of morphine skeleton in a single step. 
12 
 
Chloroselenation led to the oxo-bridged adduct 51 from 50. Deprotection of the 
keto group, Davis oxidation, and reduction resulted in 53. The re-aromatized 
derivative was formed upon Moffat oxidation and was further converted to the 54. 
 
Reagents and Conditions:  a) toluene, 100 ˚C (86%); b) PhSeCl, MeOH; c) 
H2O2, THF (80%); d) aq. HCl, THF; e) KHMDS, THF; f) 3-phenyloxaziradine, 
THF (82%); g) H2, Pd/C, THF (75%); h) TFAA, DMSO, NEt3; i) BF3•Et2O; j) 
CH3I, K2CO3 (56% over three steps).   
 
Scheme 6. Synthesis of intermediate compound 54.  
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Further, cleavage of the C-N bond and dihydrofuran rings, N-methylation 
and re-attachment of the aminoethyl bridge were the key steps to give thebainone-
A (60). 
 
Reagents and Conditions:  k) PhSeCl, EtOAc, then H2O2, THF (70%); l) 
NaBH4, MeOH; m) MeLi, THF; n) HCOH, NaCNBH3, H2O, CH3CN (54% over 
three steps); o) Dess-Martin periodinane, CH2Cl2 (75%); p) Zn, NH4Cl, EtOH, 
H2O (73%, 60% conversion); q) DIBAL-H, THF; r) H3O
+
 (quantitative); s) 
HOAc, 100 ˚C (87%).   
Scheme 7.  Tius’ synthesis of thebainone-A. 
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Hudlicky (1992, 1995, 1998)
13-15
 
In 1992, Hudlicky envisioned that the A and C rings could be constructed 
from cis-cyclohexenediol and its corresponding catechol which can be obtained 
from the bio-transformation of aromatic compounds. An adduct of these two 
pieces could lead to a Diels-Alder reaction to get the phenanthrofuran core of 
morphinan. 
 
Figure 7.  Hudlicky’s Diels-Alder strategy.   
On this basis, model studies were conducted and the key tricyclic core was 
constructed. One of the alcoholic groups was protected and other one formed an 
adduct with sorbyl bromide which gave tetraene 65, where cyclic diene was 
involved in the cycloaddition reaction. Removal of the silyl protecting group and 
oxidation of the alcohol to its ketone, then underwent into a tricyclic skeleton via 
a Cope rearrangement. Luche reduction of the unsaturated ketone gave the allylic 
alcohol 67 possessing four stereocenters of the morphine skeleton in the correct 
configuration. 
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Reagents and Conditions:  a) THSCl, imidazole; b) NaH, sorbyl bromide; c) 
CCl4, reflux; d) TBAF, then PCC, rt; e) xylenes, 250 ˚C; f) CeCl3, NaBH4, rt.   
Scheme 8. Model studies for morphine synthesis. 
With the second generation model studies the stereochemistry of 67 was 
proven to be incorrect; it was originally mis-assigned based on nOe correlations. 
The Diels-Alder adduct indicated that the cycloaddition proceeded via an exo 
transition state rather than an endo transition state. The less substituted olefin was 
reduced with the help of a diimide and the less hindered alcohol was selectively 
protected. O-alkylation with sorbyl bromide set the diene part in the molecule and 
underwent a Diels-Alder reaction to yield the tricyclic core. 
16 
 
 
Reagents and Conditions:  a) PAD, AcOH, MeOH; b) THSCl, imidazole; c) 
NaH, sorbyl bromide; d) toluene, sealed tube, 210 ˚C;  e) TBAF, THF.   
Scheme 9.  Hudlicky’s correction of morphine skeleton structure. 
The miss assigned stereochemistry was actually corrected with more 
sophisticated model studies. Biological oxidation of (2-azidoethyl) benzene 
readily available from bromoethylbenzene afforded the cis-dienediol. The less 
substituted olefin was reduced with diimide and the less hindered alcohol was 
selectively protected. Alkylation of the allylic oxygen and 71 formation set the 
triene for a Diels-Alder reaction. X-ray crystallographic analysis confirmed the 
stereochemistry of the [4+2] cycloaddition, preceded via an exo transition state. 
This result helped to reinvestigate the formal structural correction of cycloadduct 
72, giving a very direct route to construct the morphine skeleton with the correct 
stereochemistry. 
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Reagents and Conditions:  (a) E. coli JM109 (pDTG601), (10 g/L); (b) NaN3, 
DMF; (c) potassium azodicarboxylate (PAD), AcOH, MeOH (72%); (d) THS-Cl, 
imidazole, DMF (99%); (e) NaH, sorbyl bromide, THF (62%); (f) Ph3P, H2O 
(66%); (g) Ac2O, py  (quantitative); (h) toluene, sealed tube, 230 ˚C (62%); (i) 
45% aq HF, MeCN (65%).   
Scheme 10.  Hudlicky’s strategy for the B, C, D ring system synthesis of 
morphine.   
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Later, in 1995 the Hudlicky group visualized that the heteroaromatic ring 
could act as a diene for Diels-Alder reaction and would be helpful for the 
construction of isoquinoline morphine synthons. 
  
 
Figure 8.  Hudlicky’s approach for isoquinoline morphine synthons. 
 
With this vision, model studies had been conducted. In the Scheme 11 
oxazolidinone 85 underwent thermal Diels-Alder cyclizations in two ways: first 
by simple heating in toluene at 200 ˚C with a 56% yield; and second, by heating 
at much lower temperature (65-90 ˚C) in the presence of β-cyclodextrin with an 
84% yield. The stereochemistry of the model tricycle was proven by single-crystal 
X-ray analysis. Hudlicky postulated that the transition state has a chair-like 
conformation in which the furan adopted an exo-position. 
19 
 
 
 
Reagents and Conditions:  a) 90 ˚C, cyclodextrin (84%); b) OsO4, t-BuOH-H2O 
(95%).  
Scheme 11. Proposed transition state postulated for model isoquinoline 
cyclizations. 
With this preliminary result, subsequent model studies examined the 2-
methoxyfuran derivatives were studied. When R = H, the anisole 93 (40%) and 
the enone 94 (55%) were formed upon thermal cyclization but in the case of R= 
Ph the Diels-Alder reaction gave the advanced isoquinoline derivative 95 with a 
13% yield. These studies showed that morphine synthons could be constructed by 
the intramolecular Diels-Alder reaction of furans. 
20 
 
 
Scheme 12. Morphine synthons 
Rodrigo (1998)
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Rodrigo recognized that o-substituted phenolic ethers undergo oxidative 
coupling with alcohols to give mixed ketals. With this strategy, he synthesized 
ketals that contained diene and dinophile parts in a single molecule. This ketal 
readily underwent an intramolecular Diels-Alder reaction without isolation of the 
ketal adduct intermediate. Two possible Diels-Alder adducts were formed in the 
process, one with the desired stereochemistry which could be extended to form 
the morphine skeleton while the other rearranged to give 97. 
21 
 
 
Reagents and Conditions:  a) BTIB, THF ; b) [3,3]-sigmatropic rearrangement. 
 
Scheme 13. Rodrigo strategy to construct morphine skeleton.  
With this success, Rodrigo used the same strategy to make the A, B and C 
rings of morphine skeleton. Rodrigo synthesised the desired in situ ketal adduct 
from vanillate and allylic alcohol which underwent spontaneously into three 
possible Diels-Alder products. Desired Diels-Alder adduct 102 (11%) was formed 
while diastereomers 101 with (13%) and the bridged bicycle 103 with (17%) 
yield.  Thermal Cope rearrangement of 103 gave the tetracycle 104, which 
underwent rearomatization to 105 losing the methyl ester group.  Phenol was 
methylated to give the phenanthrofuran skeleton 106. 
22 
 
 
Reagents and Conditions:  a) BTIB, THF; b) DME, reflux (59%); c) NaOH, 
MeOH (94%); d) K2CO3, Me2SO4 (75%).   
 
Scheme 14. Rodrigo’s Diels-Alder/Cope approach to phenanthrofurans.                 
Stork (2009)
17
 
Stork’s strategy for the synthesis of morphine alkaloids via a highly 
stereocontrolled intramolecular 4 + 2 cycloaddition to establish the B- and C-ring 
of the morphine alkaloid. 
The Diels-Alder precursor was prepared in 6 steps from iodoisovanillin 
which was converted to 151 in two steps. An intramolecular Heck coupling gave 
152, removal of the keto group and extention of the aldehyde through a Wittig 
23 
 
reaction give 153 which was converted into the Diels-Alder precursor through 
homologation of the aldehyde. 
Then it was heated in decalin at 240 ˚C in a sealed pressure flask, in the 
presence of triethylamine to result in the desired cycloaddtion reaction. Cleavage 
of the protecting silyl ether group, oxidation to a keto group, and conversion of 
the methyl ester to its enol ether gave 156.  The C-9 ketone was reduced and 
converted to its mesylate prior to introduction of the methylamine via a reductive 
amination. The resulting methylamine group displaced the mesylate to give the 
cyclised product (+) codeine methyl ether (157). 157 is a know intermediate of 
Rappoport’s synthesis of thebaine.18 
Important features of the Stork’s synthesis were to set the correct relative 
stereochemistry of the five contiguous asymmetric carbon atoms in a single step 
reaction and only a minor diastereoisomer was formed. 
24 
 
 
Reagents and Conditions:  (a) HO(CH2)2OH, p-TsOH, toluene (85%); (b) 
methyl propiolate, Et3N, THF (89%); (c) Pd(OAc)2, Ph3P, NaOAc, n-Bu4NCl, 
DMF, 125 °C (84%); (d) HCl, THF (98%); (e) (i) Ph3PCH2OCH3Cl, KHMDS, 
THF, (ii) HCl, THF (95%); (f) (i) 4-methoxy-3-butene-1-yne, ZrCp2(H)Cl, 
AgOTf, CH2Cl2, (ii) TESCl, imidazole (95%); (g) Decalin, Et3N, 240 °C, 24 h 
(69%); (h) (i) Super hydride, THF, (ii) Dess-Martin, CH2Cl2, (iii) 
Ph3PCH2OCH3Cl, KHMDS, CH2Cl2-THF, (iv)TBAF, THF, (v) Dess-Martin, 
CH2Cl2, 0 °C (51%); (i) L-Selectride, THF, 0 °C, (ii) MsCl, Et3N, CH2Cl2, 0 °C 
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(34%); (j) (i) HCl, THF, (ii) MeNH2·HCl, Et3N, Ti(OiPr)4, MeOH, (iii) NaBH4 
(80%); (k) K2CO3, benzene, 75° C, 24 h; (l) Reference 18. 
Scheme 15. Stork’s synthesis of thebaine. 
II-3  Pyridazine 
II-3.1   Use in synthetic chemistry 
The reactivity differences of benzene and pyridine are well-known as 
compared to those of benzene and pyridazine. Some of the general features of 
pyridazine chemistry can be summarized as follows.  
Reactions with Electrophilic Reagents: 
Pyridazines are electron-deficient heterocycles and are generally resistant 
to electrophilic substitution on the pyridazine ring. The reason being, the 
aromaticity of pyridazine is distorted because of electrophilic substitution at one 
of the carbon centers of the ring, which is further deactivated by two 
electronegative nitrogens. Therefore, the electrophilic addition is more favoured 
at nitrogen. 
 
Figure 9.  Electrophilic substitution with pyridazine. 
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Alkylation: 
Pyridazines reacts with activated alkyl halides through SN2 displacement 
to give the mono-quaternary salts. Additionally, unsymmetrically substituted 
pyridazines can give rise to two isomeric quaternary salts. Substituents influence 
the orientation mainly by steric and inductive effects, rather than mesomeric 
effects. For example, 3-methylpyridazine alkylates mainly at N-1, even though N-
2 is the more electron-rich site. Yet another example is quaternisation of  3-
methoxy-6-methylpyridazine which takes place adjacent to the methyl substituent, 
at N-1, although mesomeric release would have been expected to favour attack at 
another nitrogen atom.
19
 
 
Figure 10.  Alkylation of pyridazine. 
Oxidation: 
Pyridazines react with peracids to form N-monoxides. Intrestingly, the 
regiochemistry of N-oxidation is the same as N-alkylation.  For example, 3-
aminopyridazine gives mainly 2-oxides, but 3-methylpyridazine provides the 1-
oxide as the main (3:1) product (figure 11).
20 
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Figure 11.  Oxidation of pyridazine. 
Electrophilic Subsitution at Carbon: 
The aromatic electrophilic substitution reaction is difficult to attain at the 
ring’s C- atoms as a result of the electron withdrawing nature of the N atom. 
Electrophilic substitution of pyridazine, mainly takes place in the presence of 
electron-donating substituents.
21
 It is worth noting that N-oxidation facilitates the 
substitution in some of the cases.
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4-Amino-3,6-dimethoxypyridazine undergoes nitration to afford the 5-
nitro compound. However, the less highly activated 3-methoxy-5- 
methylpyridazine requires more vigorous conditions to yield a complex mixture 
of 4-nitro, 6-nitro, and 4,6-dinitro derivatives. Pyridazine 1-oxide and many of its 
substituted derivatives undergo nitration with nitric and sulfuric acid to form the 
corresponding 4-nitropyridazine-1-oxide 125 (figure 12)
21
: 
 
Figure 12.  Electrophilic substitution reactions at carbon of pyridazine. 
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Reactions with Nucleophilic Reagents: 
The pyridazines are reactive towards nucleophilic addition due to the 
presence of nitrogen atoms. The nucleophilic substitution goes smoothly with 
good leaving groups. For example, halopyridazine react with nucleophiles with a 
halide ion as a leaving group. In addition, nucleophiles can also displace methoxy 
groups via an addition/elimination process.
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Reagents and Conditions:  (a) PhCH2CN, NaNH2, PhH, reflux (65%); (b) 
CH2(CN)2/NaH, dioxane, reflux (62%). 
Scheme 16. Nucleophic substitution of pyridazine. 
Unsymmmetrically disubstituted pyridazines can also be prepared in a 
stepwise manner. For example, nucleophilic mono-substitution is followed by a 
palladium-catalyzed coupling with an arylboronic acid.
24
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Reagents and Conditions:  (a) NaOMe/MeOH, reflux, 12 h (92%); (b) 
PhB(OH)2, Pd(PPh3)4, Na2CO3, PhMe (76%). 
Scheme 17. Synthesis of unsymmmetrically disubstituted pyridazine. 
C-H activation reactions of pyridazine: 
Pyridazines are usually difficult to ortho-metalate because of the low 
LUMO energy, which makes them reactive towards nucleophile additions. 
Because of this reason, non-nucleophilic lithium 2,2,6,6-tetramethylpiperidide 
(LiTMP) is a more efficient ortho-metalating agent than the alkyllithiums. 
However, the heteroaryllithium species are very unstable and can easily dimerize. 
These conditions could be avoided by using very short lithiation time or by in-situ 
trapping with compatible electrophiles.
25
 
 
Figure 13. C-H activation from LiTMP.  
Generally, the lithiation requires low temperature reactions. In 2007, 
Florence Mongin and co-workers reported mild condition to do ortho substitution 
of pyridazine using a zinc diamide-lithium amide mixture. Deprotonation of 
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pyridazine with ZnCl2.TMEDA and LiTMP trapped with iodine result in a good 
yield of 3-iodopyridazine in THF at reflux.
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Reagents and Conditions:  ZnCl2.TMEDA, and LiTMP, THF, 0 °C to reflux, 
(66%). 
Scheme 18.  Ortho-substitution of pyridazine using a zinc diamide-lithium amide 
mixture. 
In 2003  Kondo reported that the direct zincation of pyridazine occurs at 
position 4 instead of position 3 when using a hindered phosphazene t-BuP4 base 
and zinc (II) iodide as an additive in toluene.
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Reagents and Conditions: ZnI2, t-Bu-P4, PhMe, -78 °C to rt (73%). 
Scheme 19. Zincation of pyridazine. 
Lithiation of pyridazine with a directing group is an easy and a high 
yielding process.
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Reagents and Conditions: LiTMP, -70 °C, then 136 (65%). 
Scheme 20.  Pyridazine with a directing group. 
Ortho-lithiation of pyridazine with chiral molecules like chiral sulfinate 
esters has been reported by Queguiner and coworkers.
29
 The resulting chiral 
sulfoxides can be subjected to a second ortho-lithiation with different aldehydes 
to provide fully-substituted pyridazines with high diastereoselectivities. 
Ortho-lithiation of pyridazine with chiral molecules like chiral sulfinate esters has 
been reported by Queguiner and coworkers. The resulting chiral sulfoxides can be 
subjected to a second ortho-lithiation with different aldehydes to provide fully 
substituted pyridazines with high diastereoselectivities. 
 
Reagents and Conditions: a) LTMP, (S) or (R)-menthyl p-toluenesulfinate (76-
77%); b) LTMP or LDA, RCHO, (76-80%). 
Scheme 21. Ortho-lithiation of pyridazine with chiral molecules. 
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Coupling Reactions: 
Rival and co-workers reported the first Suzuki cross-coupling of 
pyridazine with palladium-mediated chemistry. Electron-donating substituents on 
the arylboronic acid provided optimal yields.
30
 
 
Reagents and Conditions: Pd(PPh3)4, Na2CO3, 30-60% 
Scheme 22. Cross-coupling of pyridazine. 
Similar studies on palladium-catalyzed Stille and Suzuki coupling 
reactions of pyridazinyl triflates have been reported by Aldous and co-workers 
with electron-rich arylstannanes and aryl boronates. In general, the Suzuki 
reaction was found to be more efficient than the corresponding Stille cross- 
coupling reaction.
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Figure 14. Stille and Suzuki coupling reactions of pyridazine. 
Direct amination of 3-chloropyridazines with primary amines usually 
needs harsh conditions and results in poor yielding reactions. It was found that 
palladium cross-coupling reactions form a smooth carbon–nitrogen bond. Hibert32 
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reported a palladium-assisted procedure for the amination of 3-iodo-6-
arylpyridazines 147. 
 
Reagents and Conditions: PdCl2(dppf), dppf, t-BuONa, 80 °C, 6h (75%). 
Scheme 23. Amination of compound 147.  
II-3.2 Use of pyridazine in Diels-Alder reaction 
The Diels–Alder cycloadditions of pyridazines have proven to be valuable.  
The reaction is very fundamental for the construction of key intermediate 
compounds for the synthesis of various natural products. Pyridazine rings 
generally undergo inverse electron-demand Diels-Alder reactions due to deficient 
properties of п electrons. The presence of electron withdrawing substituents on 
pyridazine ring enhances their reactivity towards electron-rich dienophiles. 
Electron withdrawing substituents lead to a decrease in its LUMO energy and 
favours inverse Diels-Alder reactions. The immediate products of such processes 
usually lose nitrogen for subsequent retro-Diels–Alder reaction. 
Pyridazines give low to moderate yielded cycloadduct products for 
intermolecular hetero Diels-Alder reactions. For example, 4,5-dicyanopyridazine 
with N-methylpyrrole reacts at 150 °C to give a Diels–Alder adduct and  
subsequent loss of H2 and N2 provide indole heterocycles.
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Reagents and Conditions: Xylene, 150 °C (55%). 
Scheme 24. Intermolecular hetero Diels-Alder reactions example. 
Intramolecular Diels–Alder reactions of pyridazines work well with 
doubly tethered pyridazine. For example, cyclophane was heated in N,N-
diethylaniline and led to the formation of pentacyclic product 156 in quantitative 
yield while the same reaction in mesitylene gave a yield of 21%.
34
  
 
Reagents and Conditions: Mesitylene, 10 d, 21% or N, N-diethylaniline, 2d 
(90%). 
Scheme 25. Intramolecular Diels–Alder reactions of pyridazines. 
In 1983 Boger investigated the effects of the length of the alkyne side 
chain (n = 1,2,3), substitution (R1 = H, C1; R2 = H, CH3, CH2OR), and 
heteroatom (X = O, NCO2CH3) on the intramolecular  thermal cycloaddition of 
pyridazine.
35
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Figure 15.  Investigation of the intramolecular  cycloaddition of pyridazine.  
The result of the study suggested that the variation in the length of the 
alkyne side chain (n = 1) and heteroatom (X= NCO2CH3) mainly affected the 
outcome of intramolecular Diels-Alder reaction of the alkyne 1,2-diazines. 
 
Reagents and Conditions: 1,3,5-triiipropylbezene, 150-250 °C, 6-24 h. 
Scheme 26. Effect of alkyne side chain and heteroatom on the Diels-Alder 
reaction. 
The substitution of R1 and R2 hardly have any effect on the rate of 
cycloaddition. 
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Reagents and Conditions: 1,3,5-triiipropylbezene, 230 °C, 12 h. 
Scheme 27. Effect of subsitution of the pyridazine ring on the Diels-Alder 
reaction. 
 
 
Reagents and Conditions: 1,3,5-triisopropylbenzene, 230 °C, 18h. 
Scheme 28. Effect of subsitution of alkyne side chain on Diels-Alder reaction. 
II-4 Previous approaches in the Hudlicky group towards the synthesis of 
thebaine  
The synthesis of thebaine is based on the latent pseudo-symmetry that is 
present in the thebaine molecule. Based on this symmetry, it is visualized that the 
thebaine core could be constructed through a cascade of sulfoxidation/ 
intramolecular Diels-Alder reactions of compound 167 (figure 16).  
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Figure 16.  The retrosynthetic analysis of thebaine using thiophene as a masked 
diene.  
With this strategy, Dr. Kevin Finn
36
 used 2-iodothiophene as a starting 
material. 2-Iodothiophene was converted to 2-methoxythiophene and then into 2-
Iodo-5-methoxythiophene. This iodo derivative was converted into compound 
169 in a single step or in a stepwise manner through a Sonogashira reaction. This 
alkyne 169 was subjected to hydroamination conditions but 169 never gave the 
desired hydroamination product 175 and only the starting material was recovered.  
 
 
 
38 
 
 
 
Reagents and Conditions: a) NaOMe, MeOH, CuO (76%); b) I2, HgO, benzene, 
CH2Cl2 (76%), c) TMS-acetylene, Pd(PPh3)4, TEBAC, CuI, benzene, 2.5 N aq 
NaOH , sealed tube (32%) ; d) TMS-acetylene, Pd(PPh3)2Cl2, 
i
Pr2NH, CuI; e) 
TBAF, THF, rt (65%); f) Pd(PPh3)2Cl2, NEt3, CuI, 171, (36%); g) toluene, 1M 
MeNH2 in THF, 120 °C, seal tube; h) toluene, MeNH2, IndTiMe2, 120 °C.  
Scheme 29. Thiophene strategy for the synthesis of thebaine. 
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Alternatively, a corresponding alkene of compound 169 was synthesized 
and subjected to a variety of aziridination conditions without any success 
(Scheme 30). 
 Scheme 30.  
At this point model studies had been done to assess the feasibility of the 
tandem oxidation/Diels-Alder sequence. Retro synthetic analysis of model studies 
are shown in figure 17 as below:  
 
Figure 17.  Retro synthetic analysis of thiophene based model. 
Commercially available 2-acetyl thiophene was used as a starting material 
and converted into compound 186 in two steps. An analogous amide of compound 
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189 was also prepared from 2-acetyl thiophene in two steps in order to determine 
the feasibility of the tandem oxidation/Diels-Alder sequence.  
 
Scheme 31. Thiophene-based model compound synthesis route. 
Reagents and Conditions: a) NaBH4, MeOH; b) DMAP, DCC, DCM (33%), c) 
methylamine, pTsOH, toluene, quant.; d) NaBH4, MeOH (68%); e) DMAP, DCC, 
DCM (39%).  
Compounds 186 and 189 were subjected to an enzymatic oxidation by 
Escherichia coli JM 109 pDTG061. Ester 186 gave a hydrolysis product and the 
amide 189 was found to be resistant to enzymatic oxidation.  
Later, the known chemical oxidation condition for thiophene was also 
investigated but only the starting material or decomposed product were observed 
for 186 and 189. Furthermore, an oxidation using mCPBA gave the epoxy product 
as shown in Scheme 32. 
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Scheme 32. Epoxy products. 
Reagents and Conditions: a) mCPBA, DCM (62%); b) mCPBA, DCM (70%). 
At this point, furan based model studies had also been investigated in 
which a furan would serve as a latent diene for an intramolecular furan Diels-
Alder reaction. 
 Furan was used as a starting material. Furan was acylated to get 2-
acetylfuran, then converted into compound 194 and this amine was coupled with 
an acid 195 to get amide 196 as shown in Scheme 33. 
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Scheme 33. Furan based model compound. 
Reagents and Conditions: a) BF3OEt, (Ac)2O; b) NH2Me, TiCl4; c) NaBH4, 
iPrOH (56% in 2 steps); d) DMAP, EDC, DCM (87%).  
The amide 196 was subjected to various Diels-Alder reaction. Sc(OTf)3 
and Yb(OTF)3 were found to be an ineffective catalysts, while AlCl3 and TiCl4 
resulted in the destruction of the starting material. Furthermore, 196 was stable for 
thermal (greater than 200 °C) Diels-Alder reaction. Compound 196 was reduced 
to corresponding 197 and was also found to be stable for thermal Diels-Alder 
reaction.  
 
Scheme 34. Thermal Diels-Alder reaction attempt.  
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Later pyridazine was chosen by Dr. Jon Collins
37
 to investigate the 
validity of intramolecular Diels Alder reactions. It was observed that two suitably 
substituted pyridazines and the appropriate furan-based dieneophile could 
undergo intramolecular Diels-Alder reactions as shown in figure 18.  
 
Figure 18.  Diels-Alder strategy for the synthesis of thebaine. 
The key intermediate 205 was synthesised to validate the Diels-Alder 
reaction. Unfortunately, 205 underwent an unexpected Hoffman-type elimination 
to give 206, as shown in Scheme 35. 
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Scheme 35. Diels-Alder reaction attempt using a bis-pyridazine strategy.  
Reaction conditions: a) HI, ICl (76%); b) MeOH, K2CO3 (72%); c) TMS 
acetylene, CuI, PdCl2(Ph3)2, Et3N,  THF, then TBAF, THF, rt (69%); d) 4, CuI, 
PdCl2(Ph3)2, Et3N, rt (71%); e) MeNH2, Ind2TiMe2, toluene, 110 °C; (f) 
NaBH3CN, MeOH, ZnCl2 (68%, 2 steps); g) LiOH, MeOH, 50 °C; h) 201,  
toluene, 150 °C; i) DMAP, Et3N, 201; j) oxalyl chloride, DMF; k) CDI, 201, 
CH2Cl2, relux; l) toluene, reflux. 
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III. Discussion 
III-1 Introduction 
Based on the historical precedents reviewed in the previous chapter, it is 
decided to pursue several model studies towards the total synthesis of thebaine. 
As previously summarized one of the problems encountered in the past was the 
elimination of the methoxy pyridazine derivatives. Therefore it is decided to focus 
on simple model studies, which would allow to quickly assessing the feasibility of 
the intramolecular Diels-Alder strategy. The pyridazine will serve as diene, as 
shown in figure 19. 
 
Figure 19.  Retro analysis for simple model studies of thebaine. 
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The results of these studies are discussed in detail in the following section. 
III-2 Model study to construct C and E ring of thebaine 
In order to determine the viability of intramolecular Diels-Alder reaction 
to construct the C and E ring of thebaine, compound 207 was envisioned to 
undergo a Diels-Alder reaction to produce compound 7, as shown in figure 20. 
 
Figure 20.  Model study to construct the C and E rings of thebaine. 
Compound 207 was prepared from compound 9 and 213. Key 
intermediate 9 was synthesized by two routes. One route was found to be tedious 
and a low yielding process in which 9 was synthesised in 8 steps with an overall 
yield of 11%. Its synthesis started with a commercially available compound 5 and 
3-iodopyridazine prepared according to literature procedures
38,39
. Compound 209 
was synthesized through a general Sonogashira reaction and then subjected to an 
oxymercuration-demercuration reaction to get compound 210. This keto 
derivative was reduced to 10 through a borohydride reduction. Then it was 
converted into key compound 9 in another 2 steps, as shown in Scheme 36. 
47 
 
 
Scheme 36. Synthesis of pyridazine amine 9 from pyridazine 5 
Reaction conditions: a) KI, ICl, (72%); b) EtOH, reflux, N2H4.H2O (90%) c) 
HgO(yellow), H2O, rt (75%); d) TMS acetylene, PdCl2(PPh3)2, CuI, NEt3, THF, rt 
(85%); e) HgSO4, H2SO4, THF, H2O, reflux (49%); f) NaBH4, MeOH, rt (83%); 
g) MsCl, NEt3, DCM; h) MeNH2, DCM, THF (66%). 
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In another route, key compound 9 was prepared in three steps with an 
overall yield of 38% and this route was found to be reliable in order to carry 
forward the model studies. The key step in this route was the selective 
ortholithiation of pyridazine 11. Literature procedure was a low yielding reaction 
of this step (26%).
25
 Slight modification gave an improved yield of compound 10, 
as shown in Table 1.  
 
Figure 21.  Ortholithiation of pyridazine. 
Table 1. Different conditions for improving the yield of compound 10. 
Conditions Result 
TMEADA, nBuLi, THF, -78 °C, 1hr Decomposition of starting material 
TMEADA, nBuLi, THF, -78 °C to 0 °C 
, 1hr 
Decomposition of starting material 
TMEADA, nBuLi, THF, 0 °C to rt, 1hr Decomposition of starting material 
LiTMP, THF, -78 °C to 0 °C, 2 hr Decomposition of starting material 
nBuLi, THF, DMAE, -78 °C, 1 hr Decomposition of starting material 
LiTMP, THF, -85 °C, 1hr 39% 
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Furthermore, it was found that without isolating compounds 10 and 211, 
isolated yield of pyridazine amine derivative 9 was improved with an overall yield 
of 38%, as shown in Scheme 37. 
 
Scheme 37. Synthesis of pyridazine amine 9 from pyridazine 11. 
Reaction conditions: a) LTMP, THF, CH3CHO, -85 
o
C; b) MsCl, Et3N, CH2Cl2, 
0 
o
C to RT; c) MeNH2, CH2Cl2, THF, -75 
o
C to rt. 
Vinyl acetic acid anhydride 213 was prepared according to a literature 
procedure
40
 and coupled with pyridazine amine 9 in the presence of DMAP to get 
the Diels-Alder precursor. The Diels-Alder reaction occurred smoothly at reflux 
in o-xylene, as shown in scheme 38.  
 
Scheme38. Diels-Alder successful attempt. 
Reaction conditions: a) CH2Cl2, DCC, rt (69%); b) DMAP, Et3N, CH2Cl2, rt (71 
%); c) o-xylene, reflux (50%). 
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 After validating the Diels-Alder reaction, a more complicated model 
study was designed, which is discussed in next section.  
III-3 Model study to construct D, C and E ring of thebaine 
 The furanyl ester derivative 202 was chosen for further model studies as a 
dienophle to construct the C, D and E ring of thebaine with pyridazine amine 9.  
 
 Figure 22.  Model study with dihydrofuran ester.  
202 was prepared according to a procedure already established in the 
group, starting from 2,3-dihydrofuran. The furan 214 was reacted with 
ethyldiazoacetate 215, which was added drop wise over a 24 h span, to get 
cyclopropane intermediate 216. Treatment with copper bronze afforded the ring 
opened ester 202 in a 53% overall yield, as shown in Scheme 39. 
 
Scheme 39. Dihydrofuran ester synthesis. 
Reaction conditions: a) Cu (Bronze), 65 
o
C, 24 hr (68%); b) Cu (Bronze), 150 
o
C, 16 hr, (63%). 
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 Once ester 202 was obtained, several attempts were made to achieve 
amide coupling with N-methyl-1-(pyridazin-3-yl)ethanamine 9 but all attempts 
failed, as shown in Table 2.  
 
Figure 23. Attempted condition to make compound 217. 
 Table 2. Attempted conditions to make compound 217. 
Condition Results 
Neat, 100 to 200 
o
C Decomposition of starting material 
DBU, triazole, neat, RT to 160 
o
C Ester was consumed, 9 (35%) was 
recovered  
DBU, triazole, trichlorobenzene, RT to 
170
 o
C 
Ester was consumed, 9 (26%) was 
recovered 
DBU, triazole, DMF, RT to 160 
o
C 9 (58%) was recovered 
n-BuLi, THF used to make anion of 
amine, then ester was added to amine 
reaction mixture at -78
 o
C, temperature 
raised to till reflux with TLC 
monitoring. 
No reaction 
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At this point compound 202 was converted into the corresponding acid 
salt 218, as shown in Scheme 40.  
 
Scheme 40. Synthesis of a potassium salt of dihydrofuranester. 
Reaction conditions: a) KOH, EtOH, 50
 o
C, 16 hr (quantitative). 
A mixed anhydride strategy was envisioned and pyridazine amine was 
attempted to achieve amide coupling with ester 202, but an undesired product 
lactone 221 was formed, as shown in Figure 24 and Table 3. 
 
Figure 24.  Mixed anhydride strategy to get an amide. 
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Table 3. Conditioned to synthesise the 217 with a mixed anhydride strategy. 
Condition Result 
Pyridine, DCM, 0 
o
C to rt, 24 h, 
filetered through Celite, then DMAP, 
Et3N and 9 were added  
220 was isolated 
Pyridine, DCM, 0 
o
C to rt, 24 h then 9 
was added 
220 was isolated 
 
As none of the reactions gave the desired Diels-Alder precursor 217, a 
lactone was chosen as a coupling partner with pyridazine amine 9, but all attempts 
failed to synthesize the desire compound 217, as shown in Table 4.  
 
Table 4. Conditioned to synthesise the 217 with lactone. 
Condition Result 
DBU, Triazole, CDCl3, reflux 9 was recovered 
Toluene, DMAP, reflux 9 was recovered 
DMF, DMAP, reflux 9 was recovered 
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Finally, potassium salt 218 coupled with pyridazine 9 in the presence of 
HBTU gave the desired Diels-Alder reaction precursor 217 which underwent a 
Diels-Alder reaction at 200 
o
C, as shown in Scheme 41. 
 
Scheme 41. Diels-Alder reaction precursor 217 which underwent an 
intramolecular Diels-Alder reaction to yield 222. 
Reaction conditions: a) HBTU, DIPEA, DMF, RT, 48 hr (69%); b) 1,2,4 
trichlorobenzene, 200 °C, 14 hr (58%). 
After this model study, furan acetic acid was chosen as a dienophile for 
the Diels-Alder reaction. A few examples that are present in literature prove that 
furan can act as a dienophile.
41,42
 With this fact, another model study is 
envisioned, as shown in Figure 25. 
 
55 
 
 
Figure 25.  Model study with 9 and 195. 
If compound 223 was formed, then another double bond of 195 could be 
used for a second Diels-Alder reaction with 201 in the synthesis of thebaine as 
shown in Figure 26.  
 
Figure 26.  Furan strategy towards the synthesis of thebaine 
Recently, it was proven that furan can act as dienophile and can undergo 
Diels-Alder reactions with 1,2-diazine derivatives in the presence of bidentate 
borane Lewis acids.
43
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With this vision, 2-furanyl acetic acid 195 was prepared in four steps from 
furan-3-carboxaldehyde according to a published procedure, as shown in Scheme 
42.
44
  
 
Scheme 42. Synthesis of furan acetic acid. 
Reaction conditions: a) NaBH4, iPrOH; b) SOCl2, Pyr; c) NaCN, H2O, DMSO; 
d) aq. KOH (6.2% in 4 steps). 
  Compound 195 was then coupled with pyridazine 9 to get compound 229. 
Compound 229 was subjected to a Diels-Alder reaction in the presence of diboran 
catalyst 230 which was prepared according to the literature procedure.
45,46
 
Unfortunately, cyclization failed to occur even at a high temperature, as shown in 
Scheme 43.  
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Scheme 43. Attempted Diels-Alder reaction with 229. 
Reaction conditions: a) HBTU, DIPEA, DMF, RT, 48 hr, 63%; b) Diglyme, 
DIPEA, 150-280 °C; c) 1,2,4 trichlorobenzene DIPEA, 150-300 °C ; d) TMSCl, 
Mg, HMPA, 100 °C (74%); e) BCl3, 1,2-DCE, 140 °C (61%); f) AlMe3, Hexane, 
rt (21%).  
III-4 Model studies using a bis-pyridazine derivative 
With the success of simple model studies, a previously stabilised route 
was followed to synthesise bis-pyridazine derivative 201. 201 was coupled with 
compound 218 in presence of HBTU as shown in scheme 44.  
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Scheme 44. Synthesis of Bis-pyridazine derivative. 
Reaction conditions: a) HI, ICl (81%); b) MeOH, reflux (52%); c) 
acetylene, Pd(OAc)2, CuI, Et3N (68%); d) MeNH2, TICl4, 
t
BuNH2, toluene, 80 
°C; e) NaBH3CN, ZnBr2, THF, rt (63% in two steps); f) HBTU, DIPEA, DMF, rt, 
48 h (89%). 
This Diels-Alder precursor (205) was reinvestigated for 4+2 
cycloaddition. Unfortunately, the thermal Diels-Alder reaction in a different 
condition, microwave reaction and Lewis acid catalysed Diels-Alder reaction 
failed to give the desired cycloadduct product, as shown in Scheme 45. 
 
 
59 
 
 
Condition 
1,2,4-trichlorobenzene, 100 ⁰C 
Benzene,,160 ⁰C en 
Me2AlCl, Benzene, 135 ⁰C 
BF3.OEt2, Benzene, 160-170 ⁰C 
Microwave irradiation (Benzene), 150 ⁰C 
 
Scheme 45. Diels-Alder reaction attempt of 205 in different condition. 
Probably the methoxy group was donating the electrons to the ring of 205 
and accelerating the elimination reaction to get a more stable pyridazine alkene 
206. 
To prevent the elimination problem, two model compounds 233 and 234 
were envisioned in which the methoxy group could be replaced by H or Cl 
groups, as shown in Figure 27.  
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Figure 27.  Bis-pyridazine-based model compounds.  
Pyridazine 235 was prepared according to the literature procedure.
47
 235 
was subjected to a standard Pd-catalyzed Sonogashira reaction and the removal of 
the silyl protecting group gave the compound 237, as shown in Scheme 46.   
 
Scheme 46. Synthesis of compound 237.  
Reaction conditions: a) NaI, HI (71%); b) PdCl2(PPh3)2, Et3N, CuI, THF; c) 
TBAF, THF (71% in 2 steps). 
The pyridazine 235 was subjected to a variety of cross coupling reactions 
with acetylene, TMS-acetylene and 237, but none of them gave the desired 
compound 238 in a reasonable yield and 238 was found to be really unstable, as 
shown in Scheme 47.  
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Scheme 47. Attempted Cross-coupling reactions. 
Conditions 
PdCl2(PPh3)2, Et3N, CuI, THF, 237 
Pd(dba)2, Bu4NOAc, DMF, 237 
Pd(OAc)2, Bu4NOAc, DMF, 237 
NaH, THF, 237 
TMS-acetylene, PdCl2(PPh3)2, DBU, CuI, Benzene, Water 
TMS-acetylene, PdCl2(PPh3)2, DBU, CuI, Benzene 
Acetylene, PdCl2(PPh3)2, Et3N, CuI, THF 
Acetylene, Pd(PPh3)4, Bu4NOAc, CuI, THF 
Acetylene, Pd(PPh3)4, Bu4NOAc, CuI, Dioxane 
Acetylene, Pd(OAc)2, PPh3, Bu4NOAc, CuI, Dioxane 
Acetylene, Pd(OAc)2, PPh3, Et3N, CuI, MeCN:H2O (3:1) 
Acetylene, PdCl2(PPh3)2, PPh3, Et3N, CuI, MeCN:H2O (3:1) 
 
 The structure of 238 was confirmed only by 
1
H NMR and mass 
spectroscopy. In parallel, 3-iodo pyridazine 133 was prepared according to the 
literature procedure in 3 steps.
37,38
 Dipyridazine alkyne 240 as prepared in another 
62 
 
3 steps and it was carried forward for the model studies. Initially, the 
hydroamination of 240 with different catalyst like TICl4 with 
t
BuNH2, AgOTf and 
AgNTf2 did not give the desired product 241.  However, the hydroamination with 
Ti(NMe2)4 gave the desired product, as shown in Scheme 48. 
 
Scheme 48. Bis pyridazine amine synthesis. 
Reaction conditions: a) KI, ICl (73%); b) EtOH, reflux, N2H4.H2O; c) 
HgO(yellow), H2O, rt (61% in 2 steps); d) TMS acetylene, PdCl2(PPh3)2, CuI, 
NEt3, THF, rt; e) TBAF, THF (74% in 2 steps); f) PdCl2(PPh3)2, Et3N, CuI, THF, 
139 (51%); g) Ti(NMe2)4, toluene, MeNH2; h) NaBH3CN, ZnCl2, MeOH (41% in 
two steps). 
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Bis-pyridazine amine was coupled with 218 and then 234 subjected to a 
Diels-Alder reaction in a sealed tube in toluene at 150 °C and provided only the 
elimination product 243, as shown in Scheme 49. 
 
Scheme 49. Unexpected elimination reaction of 234. 
Reaction conditions: a) COMU, DIPEA, DMF, rt, 22 h (73%); b) 1,2,4- 
trichlorobenzene, 150 °C (71%). 
IV. Conclusions and Future Work 
The establishment of intra-molecular Diels-Alder cycloaddition reactions 
involving pyridazine and a suitable dienophile through model studies showed 
promise as a potential route towards the synthesis of thebaine. However, 
investigations towards the synthesis of thebaine using a bis(pyridazine) 
framework have proven unsuccessful, as an unexpected Hofmann-type 
elimination occurred.  
Recently, radical cation [4+2] cycloaddtion reactions have been done of 
thermally unactive cycloaddtion reactions.
48
 It might overcome the problem of 
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Hoffman type elimination of compound 234. Future work needs a radical cation 
Diels-Alder strategy or a more refined route to overcome the Hofmann-type 
elimination.                       
For a new route, instead of using a bis(pyridazine) for an intra-molecular 
Diels-Alder cyc1oaddition reaction, a single pyridazine moiety can be used for the 
first Diels-Alder reaction and another pyridazine ring can be attached later for 
another Diels-Alder reaction, as shown in Figure 28.  
Figure 28. Retro synthetic analysis based on the first Diels-Alder reaction. 
As the synthesis relied on the first intramolecular Diels-Alder reaction, 
simple model compounds were envisioned which could allow quickly assess the 
feasibility of the Diels-Alder reaction, as shown in Figure 29.  
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Figure 29. Envisioned Diels-Alder precursor compounds.  
With this vision, the Diels-Alder precursor 250 was chosen, which become 
available in a short number of steps from commercially available 
dichloropyridazine 5. Compound 5 was converted into pyridazine ethyl ester 
derivative 252 in two steps. At this point, 252 was brominated at the benzylic 
position and then treated with methylamine. Unfortunately, the methylamine 
displaced both the bromine and ester which resulted in compound 254. Compound 
254 was subjected to a Diels-Alder reaction without any success, as shown in 
Scheme 50.  
 
Scheme 50. Diels-Alder attempt with compound 256. 
Reaction conditions: a) Cs2CO3, DMSO, 110 °C; b) DMSO, NaCl, H2O, 140 °C 
(43% in two steps); c) NaBrO3, NaHSO3, EtOAc, H2O, rt; d) MeNH2, THF, -78 
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°C to rt (65% in 2 steps); e) HBTU, DIPEA, DMF, rt, 22 h (58%); f) 180-220 °C, 
1,2,4-trichlorobenzene.  
Currently, we are focussing on synthesizing the Diels-Alder precursor 249, as 
shown in figure 30. 
 
Figure 30. Future Diels-Alder precursor compounds.  
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V. Experimental Section 
V-1 General Experimental Details  
All non-hydrolytic reactions were carried out under an argon atmosphere.  
Glassware used for moisture-sensitive reactions was flame-dried under vacuum 
and subsequently purged with argon. THF was distilled from 
potassium/benzophenone.  Methylene chloride and acetonitrile were distilled from 
calcium hydride.  FlashColumn Chromatography was performed using Kieselgel 
60 (230-400) mesh. Melting points were measured on a Thomas-Hoover melting 
point apparatus and are reported uncorrected.  IR spectra were obtained on a 
Perkin-Elmer FT-IR 1600 Series Spectrum One instrument and were recorded as 
neat samples.  
1
H and 
13
C NMR spectra were obtained on either a 300-MHz 
Bruker or a 600 MHz Varian instrument. Combustion analyses were performed by 
Atlantic Microlabs, Norcross, Georgia, USA. 
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V-2 Detailed Experimental Details 
 
 
Synthesis of N-methyl-1-(pyridazine-3-yl) ethanamine (9): 
In a flame-dried round bottom flask, under argon atmosphere, 
tetramethylpiperidene (2.07 mL, 10.0 mmol) was added in THF (74 mL). n-BuLi 
(2.26 M in Hexanes, 10.0 mmol) was added at -30 
º
C then slowly allowed to 
warm untill 0 
º
C and left for 0.5 h at 0
 º
C. Pyridazine (1.05 g, 10.0 mmol) was 
added at -85
 º
C dropwise followed by adding acetaldehyde (2.69 mL, 50.0 mmol) 
at -85
 º
C. Reaction was quenched with 3.6 mL of a HCl/ THF/ EtOH (1:1:1) 
mixture after 1.5 h under inert atmosphere. The reaction mixture was left to warm 
to room temperature then a saturated solution of sodium bicarbonate was added to 
make the reaction mixture slightly basic (pH = 8). Concentrated  under vacuum  
and extracted with CH2Cl2 (2 × 60 mL) then with CHCl3:EtOH (4:1, 3 × 30 mL). 
The organic layer was washed with brine and dried with MgSO4, filtrated, and 
concentrated under vacuum. Crude product 10 was isolated as a mixture and the 
structure was determined by 
1
H NMR. Flash column chromatography: column ran 
with EtOAc/MeOH (5 to 8%) to afford 2.12 g of yellow oil. Rf = 0.43 in 
EtOAc/MeOH (90:10); 
1
H NMR (CDC13, 300 MHz) δ: 9.00 (dd, J1 = 5.0, J2 = 
10.1, 1H), 7.30-7.83 (m, 2H), 5.10 (q, J = 6.6 Hz, lH), 1.58 (d, J = 6.6 Hz, 3H). 
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Crude product 10 (2.12 g) was placed in a flame-dried round bottom flask, 
containing CH2Cl2 (50 mL), under inert atmosphere. At 0
 º
C, triethylamine (4.71 
mL, 3.40 mmol) was added followed by the addition of mesyl chloride (2 mL, 
2.50 mmol). After 1.5 h, cold H2O (5 mL) was added and the reaction mixture 
was transferred into a separatory funnel, and a 15 mL of cold saturated solution of 
sodium bicarbonate was added. The organic layer was separated and the aqueous 
layer was washed with CH2Cl2 (5 × 50 mL) followed washing with brine, then 
dried over MgSO4, filtered and concentrated under vacuum. Crude product 211 
was isolated as a mixture by flash column chromatography: silica-gel was 
neutralized with a mixture of EtOAc/Hexane/TEA (9:1:0.5) and column ran with 
an EtOAc/Hexane/TEA (9:1:0.05) eluent to afford 1.80 g of a crude product 211 
as a yellow liquid. Rf = 0.32 in EtOAc/Hexane (9:1); 
1
H NMR (CDC13, 300 MHz) 
δ: 9.14 (dd, J1 = 5.0, J2 = 10.1, 1H), 7.26-7.69 (m, 2H), 6.01 (q, J = 6.6 Hz, lH), 
3.02 (s, 3H), 1.81 (d, J=6.6 Hz, 3H).  
Crude product 211 (1.80 g) was dissolved in 8 mL of CH2Cl2 and placed in a 
flame-dried, sealed tube. THF (10ml) was added and the temperature was 
decreased to - 75
 º
C. Excess methylamine gas was bubble into the reaction 
mixture and left at rt for 48 h. Concentrated, diluted with 20 mL of EtOAc, made 
basic with sodium carbonate solution (5mL). The organic layer was separated and 
the aqueous layer was washed with ethyl acetate (3 × 30 mL) and then with 
CHCl3/EtOH (4:1, 3 × 30 mL).  The organic layer was washed with brine and 
dried with MgSO4, filtered and concentrated under vacuum. Product 9 was 
isolated by flash column chromatography: the column was run with 
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CH2Cl2/MeOH/ NH3 (95:5:1) as the eluent and then CH2Cl2/MeOH/NH3(aq.) 
(95:8:1) to afford 1.13 g (38 % overall yield) of compound 9 as a yellow oil 
which darkened when exposed to air.  
Compound 9: Rf = 0.1 in CH2Cl2/MeOH/NH3(aq.)  (95:5:2); IR (film)   = 3400, 
3063, 2974, 2879, 1582, 1556, 1452, 1435, 823, 761 cm
-1
; 
1
H NMR (CDC13, 300 
MHz) δ: 9.08 (dd, J1 = 5.0, J2 = 10.1, 1H), 7.28-7.57 (m, 2H), 4.02 (q, 1H), 
2.33(s, 3H),  1.45 (d, J = 6.6 Hz, 3H); 
13
C NMR (CDCl3, 75 MHz) δ: 22.4, 34.4, 
59.8, 124.7, 126.9, 150.4, 166.2; HRMS-FAB calcd for C7H12N3
+
: 138.1015, 
found 138.1031. Anal. Calcd for dioxalate salt of 9, C16H24N6O4.1/4CH3OH: C, 
52.74; H, 6.64; found C, 52.41; H, 6.77.  
 
 
 
Synthesis of 1, 2-dimethyl-1, 2, 4a, 5-tetrahydroisoquinolin-3(4H)-one (207): 
In a flame-dried round bottom flask, under inert atmosphere, pyridazine (0.05 g, 
0.36 mmol) and DMAP (0.02 g, 0.14 mmol) were placed. Freshly distilled DCM 
(1.5 mL) was added, forming a pale-yellow solution, followed by the addition of 
triethylamine (0.15 mL, 1.09 mmol), and the stirred mixture was cooled down to 
0 ºC. After 10 min vinyl acetic acid anhydride (0.69 mL, 0.73 mmol) was added 
in a drop-wise fashion. After 1 h in an ice-bath the reaction mixture was left to 
warm to room temperature and stirred for 20 h. After this time the reaction 
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mixture was concentrated to dryness and the crude mixture was re-dissolved in 
DCM, washed with a saturated solution of sodium bicarbonate and the organic 
layer was dried with MgSO4, filtered and concentrated under vacuum. The 
product was isolated by flash column chromatography: silica-gel was neutralized 
with a mixture of EtOAc/MeOH/TEA (94:1:5) and the column was run with an 
eluent of EtOAc/MeOH/TEA (99:1:0.5) to afford 0.06 g (87%) of compound 7 as 
a light yellow oil.  
Compound 7: Rf = 0.53 in EtOAc/MeOH (95:5); IR (film)   = 3434, 2926, 1626, 
1435, 1402, 1338, 1274, 1131, 1080, 997, 922 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) 
δ: 9.14-minor rotamer (d, J = 4.2 Hz, 1H), 9.09-major rotamer (dd, J1 = 1.8, J2 
= 4.8 Hz, 1H), 7.49-7.39 (m, 2H), 6.12-6.02 (m, 1H), 5.99-5.89 (m, 1H), 5.18-
5.08 (m, 2H,), 3.32-minor rotamer (dd, J1 = 0.9 Hz, J2 = 7.5 Hz, 2H), 3.16-
major rotamer (dd, J1 = 0.9 Hz, J2 = 7.5 Hz ,2H), 2.89-major rotamer (s, 3H), 
2.73-minor rotamer (s, 3H), 1.79-minor rotamer (d, J = 7.2 Hz, 3H), 1.67 -
major rotamer (d, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 75 MHz) δ: 171.3, 161.7, 
150.5, 131.0, 126.8, 126.6, 117.9, 51.8, 39.0, 30.1, 15.1; HRMS-EI calcd for 
C11H15N3O: 205.1210, found 205.1215; Anal. Calcd for C11H15N3O: C, 64.37; H, 
7.37; found C, 64.12; H, 7.22.  
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Synthesis of 1, 2-dimethyl-1, 2, 4a, 5-tetrahydroisoquinolin-3(4H)-one (7):  
In a flame-dried, Ar-flushed round bottom flask, pyridazine (35 mg, 0.17 mmol) 
was added. The reaction flask was evacuated and refilled with argon. This step 
was repeated a further two times then o-xylene (3mL, 0.06 M) was added under 
an argon atmosphere. The reaction mixture was left under reflux at 156  C for 26 
hs. Then reaction mixture was cooled to rt and product 7 was isolated by flash 
column chromatography: first hexane (50 mL) was used as the eluent to remove 
o-xylene then 4:1 Hx/ EtOAc (100 mL) and 2:1 Hx/ EtOAc (100 mL) eluent 
mixtures were used to afford 14 mg (50% ) of compound 7 as a light yellow oil.  
Compound 7: Rf  = 0.30 in EtOAc/MeOH (95:5); IR (film)   = 2923, 2851, 1739, 
1626, 1552, 1459, 754, 716 cm
-1
;  
1
H NMR (CDCl3, 300 MHz) δ: 5.89-5.66 (m, 
3H), 3.87-3.80(q, J = 6.6 Hz, 1H), 2.94 (s, 3H), 2.92-2.88(m, 1H), 2.85-2.04 (m, 
4H), 1.36 (d, J = 6.6 Hz, 3H). 
13
C NMR (CDCl3, 75 MHz) δ: 169.8, 137.2, 124.3, 
122.6, 117.8, 60.3, 38.9, 32.7, 29.1, 27.6, 20.1; HRMS-EI calcd for C11H15NO 
(M
+
): 177.1146, found 177.1153; Anal. Calcd for C11H15NO: C, 74.54; H, 8.53; 
found C, 74.27; H, 8.72.  
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Synthesis of potassium 2-(4, 5-dihydrofuran-3-yl) acetate (218): 
In a flame-dried round bottom flask, under an argon atmosphere, the dihydrofuran 
ester (0.34 g, 2.18 mmol) was added in absolute EtOH (6 mL) followed by KOH 
(0.12 g, 2.18 mmol). Once the KOH dissolved in the EtOH, the temperature was 
raised to 54 ºC. After 16 h the reaction mixture was cooled to rt, concentrated and 
washed with pentane to afford 0.34 g of a light yellow solid compound 218 
quantitatively.  
Compound 218: mp 195-197 ˚C (EtOH); IR (KBr)   = 3411, 3122, 2969, 2898, 
2852, 1563, 1388 cm
-1
; 
1
H NMR (D2O, 300 MHz) δ: 6.13 (s, 1H), 4.25 (t, 2H, J= 
9.3 Hz), 2.86 (d, 2H, J= 0.9 Hz), 2.49-2.59 (m, 2H); 
13
C NMR (D2O, 150 MHz) δ: 
180.6, 140.2, 111.7, 70.1, 34.9, 31.6; HRMS-FAB calcd for C6H7O3K2
+
: 
204.9664, found 204.96582; Anal. Calcd for C6H7O3K·1/2 H2O: C, 41.13; H, 
4.55; found C, 41.20; H, 4.69.  
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Synthesis of 2-(4,5-dihydrofuran-3-yl)-N-(1-pyridazin-3-ylethyl)acetamide 
(217): 
In a flame-dried 25 mL round bottom flask, under an atmosphere of argon, 
activated molecular sieves (3 Å) were introduced followed by DMF (1 mL) and 
compound 218 (0.27 g, 1.64 mmol) at rt. Then diisopropylethylamine (0.47 mL, 
2.73 mmol) and HBTU (0.50 g, 1.31 mmol) were successively added and stirred 
for 2.5 h. A solution of pyridazine 9 (0.15 g, 1.09 mmol) in DMF (2 mL) was 
added to the reaction mixture and the reaction was left overnight. Then reaction 
mixture was filtered through a celite plug which was washed with EtOAc (35 
mL), concentrated and resuspended in EtOAc (10 mL), and diluted with saturated 
solution of Na2CO3 (2 mL). The organic layer was separated and the aqueous 
layer was washed first with EtOAc (2 × 50 mL) then with CHCl3/EtOH (4:1, 2× 
30 mL). The organic layers were combined, washed with brine, dried over 
MgSO4, filtered and concentrated. Product 13 was isolated by flash column 
chromatography: the column was run with a gradient of EtOAc/ MeOH (100:0 
and 98: 2) to afford 0.18 g (69%) of compound 217 as a yellow liquid which 
darkened when exposed to air. 
 Compound 13: Rf = 0.18 in EtOAc/MeOH (95:5); IR (film)   = 3061, 2977, 
2939, 1634, 1582, 1478, 1434, 1400 cm
-1
; 
1
H NMR (CDC13, 300 MHz) δ: 9.14-
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minor rotamer (d, J = 1.8 Hz,1H), 9.10-major rotamer (t, J = 1.8 Hz,1H), 7.35-
7.48 (m, 2H), 6.17 (s, 1H), 6.09 ( q, J = 7.2 Hz, 1H), 4.35 (t, J = 9.3 Hz, 2H), 
2.92-major rotamer (s, 3H), 3.51 (s,2H), 2.76-minor rotamer (s, 3H), 2.63 (t, J 
= 9.3 Hz, 2H), 1.79-minor rotamer (d, J = 2.5 Hz, 3H), 1.68-major rotamer (d, 
J = 2.5 Hz, 3H); 
13
C NMR (CDCl3, 75 MHz) δ: 170.9, 161.8, 150.6, 142.4, 126.7, 
107.8, 70.1, 51.9, 32.3, 32.2, 30.4, 15.3.; HRMS-EI calcd for C13H17N3O2: 
247.1315, found 247.1320. 
 
 
 
Synthesis of 1,2,5,6-tetrahydro-1,2-dimethyl-4H-furo[3,2-e]isoquinolin 
3(7aH)-one (222):  
In a flame-dried, Ar-flushed sealed tube, compound 217 (0.02 g, 0.08 mmol) was 
injected, then 1,2,4-trichlrobenzene (3 mL, 0.04 M) was added under an argon 
atmosphere. The sealed tube was evacuated and backfilled with argon (this 
procedure was repeated three times). The reaction mixture was kept at 190 ºC for 
26 h in a sealed tube under an argon atmosphere. Product 222 was isolated by 
flash column chromatography: first EtOAc/hexane (1:9, 50 mL) was used as an 
eluent to remove 1,2,4-trichlrobenzene, then a gradient of EtOAc/MeOH (100:0 
and 98:2) was used to afford 0.01g (58%) of compound 222 as a yellow oil.  
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Compound 222: Rf = 0.33 in EtOAc/MeOH (95:5); IR (film)   = 3042, 2979, 
2871, 1644, 1487, 1447, 1400, 753 cm
-1
; 
1
H NMR (CDC13, 300 MHz) δ: 6.04-
5.98-major diastereoisomer (m, 1H), 5.81-5.80-minor diastereoisomer (m, 
1H), 5.79-5.72(m, 2H), 4.32-major diastereoisomer (d, J = 3.3 Hz), 4.31-major 
diastereoisomer (d, J = 3.3 Hz), 4.22-4.19-major diastereoisomer (m, 1H), 
4.18-4.01-minor diastereoisomer (m, 1H), 3.77-3.69-major diastereoisomer 
(m, 2H), 3.67-3.56-minor diastereoisomer (m, 2H), 3.00 (s, 3H), 2.48-2.26-
major diastereoisomer (m, 2H), 2.00-2.04 (m, 2H), 1.49-1.46-minor 
diastereoisomer (d, J = 4.8 Hz, 2H), 1.43-1.41-major diastereoisomer (d, J = 
4.8 Hz, 2H); 
13
C NMR (CDCl3, 75 MHz) δ: 169.5, 141.7, 125.1, 123.5, 122.2, 
116.5, 115.4, 82.1, 81.3, 63.41, 60.11, 56.5, 43.8, 42.0, 38.2, 32.4, 32.3, 23.0, 
20.4; HRMS-EI calcd for C13H17NO2(M
+
): 219.1259, found 219.1252; Anal. 
Calcd for C13H17NO2: C, 71.21; H, 7.81; found C, 71.01; H, 7.95.  
 
 
 
Synthesis of 3-chloro-6-(trimethylsilyl)ethynyl)pyridazine (236): 
A 25 mL flame-dried round-bottomed flask equipped with a magnetic stir bar, 
rubber septa, and an argon inlet was charged with freshly distilled THF (2 mL), 3-
chloro-6-iodopyridazine (0.20 g, 0.84 mmol) and cooled to 0 ºC via an ice bath.  
77 
 
To this solution triethylamine (0.70 mL, 5.04 mmol) was added and allowed to 
stir for 5 min followed by addition of trimethylsilylacetylene (0.13 mL, 0.92 
mmol), copper (I) iodide (0.08 g, 0.04 mmol), and PdCl2(PPh3)2 (0.03 g, 0.04 
mmol).  The reaction was allowed to stir at 0 °C for 1 h then warmed to room 
temperature and stirred until consumption of the starting material was observed 
via TLC (~ 4 h).  When complete, the mixture was filtered through a celite plug 
and washed with ethyl acetate (30 mL).  The filtrate was concentrated in vacuo 
and the dark brown oil was subjected to column chromatography (hexane:ethyl 
acetate, 9:1) affording 0.141 g of 3-chloro-6-((trimethylsilyl)ethynyl)pyridazine 
as a pale yellow oil and used for another step.   
Compound 236: Rf  = 0.6 (hexane:ethyl acetate, 2:1); IR (film) ν = 3007, 2964, 
1564, 1521, 1392, 1253, 1235, 1143, 862, 847 cm
-1
; 
1
H NMR (300 MHz, CDCl3) 
δ: 7.51 (q, J = 8.2 Hz, 2H), 0.28 (s, 9H); 13C NMR (75 MHz; CDCl3): δ 155.1, 
146.8, 131.8, 127.5, 102.2, 99.3, -0.5; HRMS-EI Calcd for C9H11N2SiCl (M
+
): 
210.0380, Found: 210.0380. 
 
 
 
 
 
78 
 
 
Synthesis of 3-chloro-6-ethynylpyridazine (237):  
A 10 mL flame dried round-bottomed flask equipped with a magnetic stir bar, 
rubber septum, and argon inlet was charged with freshly distilled THF (3.7 mL) 
and crude of 3-chloro-6-(trimethylsilyl)ethynyl pyridazine  (0.09 g, 0.46 mmol). 
To this solution TBAF (0.70 mL, 1 M in THF, 0.70 mmol) was added and the 
solution turned dark red.  The reaction was immediately quenched with saturated 
ammonium chloride (5 mL) and the aqueous layer was extracted with ethyl 
acetate (3 x 20 mL).  The organic layers were combined, dried with sodium 
sulfate, filtered, and concentrated in vacuo affording a dark red oil. The oil was 
subjected to column chromatography (hexane: ethyl acetate, 4:1) affording 0.05 g 
(71% in two steps) of 3-chloro-6-ethynylpyridazine as a white solid yield.  
Compound 237: 152 ºC (decompose, Et2O); Rf = 0.3 (hexane:ethyl acetate, 2:1); 
IR (film) ν = 3621, 3302, 3011, 2962, 2928, 2873, 2125, 1731, 1565, 1530, 1520, 
1450, 1392, 1301, 1148, 1067, 1046, 908 cm
-1
; 
1
H NMR (300 MHz; CDCl3): δ 
7.57 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 3.48 (s, 1H); 
13
C NMR (75 
MHz; CDCl3): δ 155.7, 146.2, 131.9, 127.7, 83.3, 78.9; HRMS-EI Calcd for 
C6H3ClN2 (M
+
): 137.9985, Found: 137.9985. Anal. Calcd for C6H3ClN2: C, 
41.13; H, 4.55; found C, 41.20; H, 4.69.  
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Synthesis of 3-Ethynylpydridazine (239): 
A flame dried round-bottomed flask equipped with a magnetic stir bar, rubber 
septum, and an argon inlet was charged with freshly distilled THF (50 mL), 3-
iodopyridazine (1.68 g, 8.20 mmol), PdCl2(PPh3)2 (0.28 g, 0.41 mmol), copper (I) 
iodide (0.08 g, 0.41 mmol) and triethylamine (3.43 mL, 24.60 mmol). The 
suspension was stirred and degassed using a stream of argon for 15 minutes. To 
this solution trimethylsilylacetylene (1.51 mL, 10.66 mmol) was added dropwise 
and the reaction was allowed to stir for 12 h. The mixture was filtered through a 
Celite plug and washed with methylene chloride (30 mL). The filtarate was 
washed with 10 mL sat. solution of ammonium chloride. The aqueous layer was 
extracted twice with 20 mL of methylene chloride. The organic layers were 
combined, concentrated in vacuo affording a dark brown oil which was dissolved 
in 20 mL of THF and treated with a tetrabutylammonium fluoride solution (12.30 
mL, 1 M in THF, 12.30 mmol) at 0 °C (under an argon atmosphere). After 10 min 
the reaction mixture was treated with 20 mL sat. solution of ammonium chloride 
and 50 mL methylene chloride. The mixture was transferred to a separatory 
funnel and the aqueous layer was separated from the organic layer. The aqueous 
phase was extracted three times with 20 mL portions of methylene chloride. The 
organic layers were combined, washed with brine, and dried over Na2SO4. The 
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solvent was removed in vacuo and subjected to flash column chromatography 
(hexane: ethyl acetate, 4:1 to 1:1) to afford 710 mg of 3-ethynylpyridazine (82%) 
as a white solid which turned to a yellow powder when exposed to air.  
Compound 239: 124-126 ºC (hexane:ethyl acetate); Rf = 0.1 (hexane:ethyl 
acetate, 1:1); IR (film) ν 3307, 3005, 2120, 1569, 1423, 1369, 1231, 1072, 1009, 
812, 655 cm
-1
; 
1
H NMR (300 MHz; CDCl3): δ 9.15 (dd, J = 5.0, 1.6 Hz, 1H), 7.61 
(dd, J = 8.5, 1.7 Hz, 1H), 7.48 (dd, J = 8.5, 5.0 Hz, 1H), 3.44 (s, 1H); 
13
C NMR 
(75 MHz; CDCl3): δ 149.9, 147.3, 129.9, 125.7, 81.9, 79.9; HRMS-EI Calcd for 
C6H4N2 (M+): 104.0374, Found: 104.0374. 
 
 
 
Synthesis of 1,2-di(pyridazin-3-yl)ethyne (240):  
A flame dried round-bottomed flask equipped with a magnetic stir bar, rubber 
septum, and an argon inlet was charged with freshly distilled THF (10 mL), 3-
iodopyridazine (0.37g, 1.82 mmol), copper (I) iodide (0.01 g, 0.076 mmol), 
PdCl2(PPh3)2 (0.05 g, 0.076 mmol), and triethylamine (0.64 mL, 4.56 mmol). The 
suspension was stirred and degassed using a stream of argon for 15 minutes. To 
this solution 3-ethynylpyridazine (0.21 g, 2.00 mmol) in 2 mL of THF was added 
dropwise and the reaction was allowed to stir for 12 h. The mixture was filtered 
through Celite and the filter plug was washed with methylene chloride (30 mL). 
The mother liquor was concentrated in vacuo and the product was isolated by 
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flash column chromatography: silica-gel was neutralized with a mixture of 
EtOAc/Hexane (1:4) with 5% TEA and column was run with an eluent of 
EtOAc/Hexane (1:4), EtOAc (100%) and EtOAc/MeOH/TEA (99:5:0.5) to afford 
241 mg of 1,2-di(pyridazin-3-yl)ethyne as a pale yellow solid (59%) which turned 
to yellow-brown solid when exposed to air.   
Compound 240: 187 ºC (ether)/(decomposed); Rf = 0.1 (ethyl acetate); IR (film) ν 
= 2967, 2637, 2467, 1599, 1577, 1443, 1226, 1086, 1023 cm
-1
;  
1
H NMR (300 
MHz, CDCl3) δ: 9.24 (t, J = 2.5 Hz, 1H), 7.82 (dd, J = 8.4, 1.3 Hz, 1H), 7.57 (dt, 
J = 8.6, 4.4 Hz, 1H); 
13
C NMR (75 MHz; CDCl3): δ 150.1, 147.2, 130.2, 125.9, 
89.1; HRMS-EI Calcd for C10H6N4 (M+): 182.0592, Found: 182.0592. 
 
 
 
Synthesis of N-methyl-1,2-di(pyridazin-3-yl)ethanamine (241): 
In a flame-dried, Ar-flushed sealed tube, 1,2-di(pyridazin-3-yl)ethyne (0.15g, 0.82 
mmol) was added and cooled externally to -50 ºC. Ti(NMe2)4 (0.2 M solution in 
toluene, 0.41mL, 0.08mmol) in 2.5 mL toluene was added in a seal tube and the 
reaction mixture was bubbled with excess methylamine gas for 5 min. The sealed 
tube was capped and allowed to warm to room temperature with stirring in a span 
of 20 min. The flask was placed in an oil bath and heated externally to 37 °C for 
40 min and then allowed to cool to room temperature. The reaction was cooled to 
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-10 ºC and argon was bubbled through until methylamine was no longer detected 
by Alkacid paper. A mixture of NaBH3CN (0.10g, 1.65 mmol) and ZnCl2 (0.11g, 
0.82 mmol) in methanol (6 mL) was added at rt and stirred for 20 h. Methylene 
chloride (20 mL) and a saturated Na2CO3 solution (10 mL) were added. The 
resulting mixture was filtered and the solid residue was washed with methylene 
chloride (50 mL). After extraction, the organic layer was separated. The aqueous 
layer was extracted with methylene chloride (5 × 20 mL) and the combined 
organic layers were dried with Na2SO4, filtered, and concentrated. Flash column 
chromatography: the column was run with CHCl3/Et2NH (0 to 5%) then 
CHCl3/Et2NH/MeOH (95:3:2) to afford 0.11g (41%)  dark yellow oil (compound 
241) which turned dark brown in colour after some time.  
Compound 241: Rf  = 0.24 (25% Et2NH in CHCl3); IR (film) ν = 3691, 3338, 
3025, 2994, 2857, 2802, 1602, 1582, 1556, 1478, 1435, 1397, 12341106, 1083, 
1013 cm
-1
;  
1
H NMR (300 MHz, CDCl3) δ: 9.10 (d, J = 4.9 Hz, 1H), 9.06 (d, J = 
4.6 Hz, 1H), 7.61 (d, J = 8.3 Hz, 1H),  7.44 (dd, J1 = 8.3, J2 = 4.9 Hz, 1H), 7.38-
7.28 (m, 2H), 4.45 (t, J = 6.8 Hz, 1H), 3.52-3.45 (m, 2H), 2.3 (s, 1H) ; 
13
C NMR 
(75 MHz; CDCl3): δ 164.4, 160.9, 150.6, 149.9, 127.5, 126.6, 126.4, 126.0, 64.2, 
42.4, 34.4; HRMS-EI Calcd for C11H13N5 (M+): 215.1175, Found: 215.1171. 
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N-(1,2-di(pyridazin-3-yl)ethyl)-2-(4,5-dihydrofuran-3-yl)-N-methylacetamide 
(234): 
To a flame-dried, argon-flushed round-bottomed flask was added compound 241 
(0.06g, 0.28 mmol) in DMF (2 mL). Activated molecular sieves (4 Å) were 
introduced at < 10 ºC and stirred for 10 min. Diisopropylethylamine (0.12 mL, 
0.69 mmol), compound 12 (0.05 g, 0.42 mmol) and COMU (0.12 g, 0.28 mmol) 
were successively added. The reaction mixture was allowed to warm to room 
temperature with stirring and allowed to stir for another 14 h. The mixture was 
filtered through Celite and the filter plug was washed with methylene chloride (30 
mL). The mother liquor was concentrated in rotawap then in high vacuo for 8 h to 
remove the DMF. Flash column chromatography: the column was run with 
CHCl3/Et2NH (0 to 5%) to afford 0.06g light brown oil compound 234 (73%) 
which turned dark brown in colour after some time. 
Compound 234: Rf = 0.42 (25% Et2NH in CHCl3); ); IR (film) ν = 3696, 3001, 
2957, 2924, 2853, 1642, 1604, 1583, 1396, 1266, 1095, 1013, 871 cm
-1
; 
1
H NMR 
(CDC13, 300 MHz) δ: 9.14 (dd, J1 = 3 Hz, J2 = 4.8 Hz,1H), 9.10 (dd, J1 = 1.2 Hz, 
J2 = 4.8 Hz,1H), 7.55-7.37 (m, 4H), 6.58-major rotamer (dd, J1 = 3.6 Hz, J2 = 
9.3 Hz,1H), 6.22-minor rotamer (dd, J1 = 7.5 Hz, J2 = 15 Hz,1H), 6.02 (s, 1H), 
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4.28 (m, 2H), 3.01 (s, 1H), 2.99-major rotamer (s, 3H), 2.76-minor rotamer (s, 
3H),2.64-minor rotamer (m, 2H), 2.39-major rotamer (m, 2H);
13
C NMR (75 
MHz; CDCl3): δ171.4, 160.4, 160.3 150.9, 149.9, 142.5, 127.1, 127.0, 126.9, 
126.3, 107.45, 70.11, 56.05, 35.62, 32.14, 31.88, 31.06; HRMS-EI Calcd for 
C17H19N5O2 (M+): 325.1529, Found: 325.1538. 
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VI. Selected Spectra  
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